Challenges and opportunities to change the course of the opioid epidemic: a surgeon’s perspective

G. Mancini

DOI: https://doi.org/10.1080/00325481.2017.1268901

2017-01-02

Postgraduate Medicine

Abstract:The US opioid epidemic is a public health crisis. Approximately 78 Americans die every day from opioid-related overdoses and prescription opioids are involved in at least half of those deaths [1]. It appears the current crisis may be an unintended consequence of well-intentioned initiatives designed to raise clinicians’ awareness of the problem of inadequate pain management and encourage more aggressive treatment of pain. In the 1990s, the phrase ‘pain as the 5th vital sign’ was coined by the American Pain Society to bring pain management to the forefront of routine patient care [2]. In 2000, Congress declared the next 10 years to be the ‘Decade of Pain Control and Research,’ to encourage advances in pain research and treatment [3]. In 2002, the Centers for Medicare & Medicaid Services and the Agency for Healthcare Research and Quality established the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey of patient satisfaction to improve transparency and develop accountability for the quality of pain management and other aspects of care provided during a patient’s hospital stay [4]. The HCAHPS survey is part of a ‘pay for performance’ model used to calculate reimbursements to hospitals [4]. As a result of heightened awareness and accountability, ‘titrating opioids to effect’ through use of pain rating scales has become the standard of care for pain management. More subtle internal influences, such as pressure to gain favorable HCAHPS patient satisfaction scores and the desire to avoid unfavorable patient ratings and negative comments on web-based physician-rating sites, have also played a role in changing the culture of pain management during the past 20 years. These factors, along with an absence of adequate patient education and insufficient provider knowledge regarding risks of overreliance on prescription opioids, have swung the pendulum from one extreme—the perception that pain should be treated more aggressively, to the other—the exponential increase in demand for opioids that has resulted in the current healthcare crisis. Between 1997 and 2007, the average per-person opioid supply in morphine equivalents increased by 700% in the United States [5]. As clinicians, we are now charged with finding ways to achieve good pain management while minimizing opioid use. Overall, 99% of US surgical patients are given postsurgical opioids [6], an indicator of the current overreliance on opioids. Opioid exposure, even in opioid-naïve surgical patients and when appropriately prescribed for short-term use, puts patients at risk for long-term opioid use [7–9] and abuse [10]. Some of the most commonly performed surgeries (total hip arthroplasty, total knee arthroplasty, laparoscopic or open cholecystectomy, open appendectomy, cesarean delivery, and simple mastectomy) are associated with an increased risk of chronic opioid use [8]. The problem of opioid abuse has prompted pharmaceutical manufacturers to develop abuse-deterrent opioid formulations that are less rewarding or more difficult to use for nonmedical purposes [11]. For example, the current formulation of OxyContin® (extended-release oxycodone) is more difficult to break, dissolve, or crush than the original formulation [11]. Some abuse-deterrent formulations, such as OxyContin, Hysingla® ER (extended-release hydrocodone), and Zohydro® ER (extended-release hydrocodone), form a gel if they are dissolved so they cannot be easily injected through a hypodermic needle [11]. TRV130 (Trevena, Inc, King of Prussia, PA) is a G-protein-biased ligand of the μ-opioid receptor that is being developed for intravenous use as an alternative to fentanyl and morphine [12,13]. TRV130 provides potent analgesia with reduced gastrointestinal and respiratory dysfunctional effects compared with morphine [13]. In 2014, the Drug Enforcement Administration (DEA) rescheduled hydrocodone combination products—the most frequently prescribed opioids—from schedule III to the more restrictive category of schedule II in response to the increasing misuse and diversion of prescription opioids [14]. Ironically, this ruling, which made hydrocodone more difficult to prescribe, may have further contributed to misuse and diversion. Surgeons became more likely to prescribe larger quantities of opioids and/or more refills than needed because of the DEA’s new restrictions on the physicians’ ability to call in opioid prescriptions to pharmacies. Overall, this change in prescribing patterns has produced an accumulation of surplus pills, which facilitates misuse, development of long-term opioid use, and diversion. A